Loading...
01/11 03:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Basic Financial Performance: 3 - Revenue growth and reduced losses are positive, but a registered direct offering and supply chain issues are concerning.\nProduct Development and Business Update: 3 - Positive FDA approval, but regulatory delays and demand fluctuations are negative.\nMarket Strategy: 3 - Expansion plans are promising, but economic conditions pose risks.\nExpenses and Financial Health: 3 - Decreased expenses are good, but increased operational activity raises concerns.\nShareholder Return Plan: 2 - Registered direct offering at a discount is negative.\nQ&A insights: Analysts showed cautious optimism, but uncertainties remain.\nConsidering market cap, a neutral stock price movement is expected.
Total Revenue $40.2 million, an increase of 4.5% from the year-ago period.
Gross Profit $25.7 million or 63.9% of revenue, compared to $26.1 million or 67.7% of revenue for the same period in 2023.
SG&A Expenses $34.1 million, a decrease of approximately $5.9 million from $40 million in the third quarter of 2023.
R&D Expenses $4.8 million, a decline of approximately $2.3 million from the same quarter a year ago.
Total Operating Expenses $38.9 million, a decrease of approximately $8.2 million from the year-ago period.
Net Loss from Operations $13.1 million, compared to a net loss of $21 million in the same period in 2023.
Adjusted EBITDA Loss of $7 million, compared to a loss of $16.3 million in the third quarter of last year.
Cash Used in Quarter $14.9 million, compared to $38 million last year.
Cash Position $39.7 million on September 30, with a pro forma cash position of approximately $114 million after recent capital raises.
Inventory Increase Inventory increased in preparation for the U.S. introduction of Motiva.
Accounts Receivable Increase Accounts receivable were higher due to increased sales to distributors.
Motiva Implants Launch: The approval of Motiva Implants on September 26 was a watershed moment for the company, with onboarding of over 250 accounts and more than 70 placing orders within three weeks.
Mia Femtech Expansion: Mia Femtech is now offered in 29 cities globally, with 78 certified plastic surgeons and 47 clinics under negotiation for certification.
U.S. Market Growth: The U.S. market is expected to exceed $35 million in revenue in 2025, driven by the successful launch of Motiva and strong demand.
China Market Development: The company is on track to achieve $10 million in stocking orders in China, with a strategic financing agreement for $50 million to support growth.
Cost Reduction Initiatives: Operating expenses decreased by approximately $8.2 million year-over-year, with a focus on reducing cash use and improving operational efficiencies.
Manufacturing Facility Decommissioning: The company decommissioned one of its manufacturing facilities to consolidate operations and drive additional cost savings.
Equity Raise: Completed a registered direct offering to raise $50 million at a 5% discount to support U.S. growth initiatives.
Sales Force Expansion: The sales force in the U.S. is expected to grow from 32 to 40 by year-end, with plans for further expansion in 2025.
Macroeconomic Pressures: Global demand remains uneven due to macroeconomic pressures, particularly affecting the breast implant industry, where demand is influenced by women's ability to pay for procedures.
Latin America Market Challenges: Latin America, especially Brazil, is underperforming with demand for breast procedures down as much as 50% in certain regions.
Supply Chain Challenges: The decommissioning of one manufacturing facility has created short-term supply challenges, impacting the ability to meet near-term demand.
Regulatory Risks: The company is in discussions with the FDA regarding the regulatory pathway for Mia and Ergonomix2, which could present risks if approvals are delayed.
Competitive Pressures: The U.S. market is highly competitive, and while the company is seeing strong initial demand, sustaining this momentum will be crucial.
Economic Factors: The company is planning conservatively for 2025, not assuming a significant rebound in Brazil or other markets, which could impact growth expectations.
FDA Approval of Motiva Implants: The approval of Motiva Implants on September 26 was a watershed moment for the company, leading to a strong launch and onboarding of new accounts.
Capital Infusion: Completed a registered direct offering to raise $50 million and accessed $25 million under an existing credit facility to support U.S. growth initiatives.
Manufacturing Optimization: Decommissioned one manufacturing facility to drive cost savings and optimize operations.
Sales Force Expansion: Increased sales representatives from 32 to 40 by year-end to support U.S. market growth.
Mia Femtech Expansion: Mia Femtech is being rolled out globally, with 29 cities and 78 certified surgeons, aiming to establish a new category in breast aesthetics.
Investment in China: Secured a strategic financing of up to $50 million to support Motiva's growth and regulatory approvals in China.
Revenue Guidance for 2024: Updated revenue guidance for 2024 to $165 million to $168 million, considering uneven market demand.
U.S. Revenue Expectations for 2025: Expect U.S. revenue to exceed $35 million in 2025, driven by strong demand for Motiva.
EBITDA Outlook: Planning for the first positive EBITDA quarter in 2025, with a conservative approach to budgeting.
Gross Margin Expectations: Expect gross margins in 2024 to be approximately 100 basis points higher on an underlying basis, with significant improvement anticipated in 2025.
Operating Expense Management: Focused on managing operating expenses, with a reduction of $19 million in operating spending over the first nine months of 2024.
Registered Direct Offering: Completed a registered direct offering to invest $50 million at a 5% discount to the closing price.
Credit Facility: Accessed $25 million under existing credit facility and amended it to access an additional $25 million until the end of 2025.
The earnings call highlights strong financial performance with record high revenue, positive EBITDA, and increased cash position. The company raised its revenue guidance and expects continued growth in the U.S. and international markets. The Q&A session confirmed positive momentum, strong market share goals, and strategic expansions. Despite some uncertainties, the overall sentiment is very positive, especially with significant growth expectations and strategic initiatives in place. Given the company's small-cap status, a strong positive stock price reaction is anticipated.
The earnings call highlights strong financial performance with double-digit growth in Latin America and a 27% growth in European direct markets. Despite challenges in China, the U.S. market shows good growth and market share gains. Positive guidance for U.S. revenues and strategic focus on account expansion and utilization suggest a positive outlook. The Q&A session confirms strong U.S. growth, premium pricing, and effective inventory strategies, though some uncertainties remain regarding China. Given the company's small-cap status, the stock is likely to react positively in the short term.
The earnings call highlights several positive factors: a 41% revenue increase, improved gross profit margins, and reduced net loss and EBITDA loss compared to the previous year. The company has a strong cash position and expects significant revenue growth in 2025. However, competitive pressures and foreign currency volatility pose risks. The absence of a shareholder return plan is offset by operational improvements and positive guidance. Given the small market cap, these factors suggest a positive stock price movement of 2% to 8% over the next two weeks.
Basic Financial Performance: 3 - Revenue growth and reduced losses are positive, but a registered direct offering and supply chain issues are concerning.\nProduct Development and Business Update: 3 - Positive FDA approval, but regulatory delays and demand fluctuations are negative.\nMarket Strategy: 3 - Expansion plans are promising, but economic conditions pose risks.\nExpenses and Financial Health: 3 - Decreased expenses are good, but increased operational activity raises concerns.\nShareholder Return Plan: 2 - Registered direct offering at a discount is negative.\nQ&A insights: Analysts showed cautious optimism, but uncertainties remain.\nConsidering market cap, a neutral stock price movement is expected.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
